Metabolism and disposition of zamicastat in rats.

disposition, rat metabolism pharmacokinetics zamicastat

Journal

Xenobiotica; the fate of foreign compounds in biological systems
ISSN: 1366-5928
Titre abrégé: Xenobiotica
Pays: England
ID NLM: 1306665

Informations de publication

Date de publication:
02 Oct 2024
Historique:
medline: 3 10 2024
pubmed: 3 10 2024
entrez: 3 10 2024
Statut: aheadofprint

Résumé

The metabolism and disposition of zamicastat, a reversible dopamine β-hydroxylase (DβH) inhibitor, developed for treatment of Pulmonary Arterial Hypertension (PAH), were investigated in rats after oral and intravenous administration of [

Identifiants

pubmed: 39359020
doi: 10.1080/00498254.2024.2411993
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-16

Auteurs

Francisca Araújo (F)

Department of Research and Development, BIAL - Portela & Ca. S.A., S Mamede do Coronado, Portugal.

Maria Luisa Dória (ML)

Department of Research and Development, BIAL - Portela & Ca. S.A., S Mamede do Coronado, Portugal.

Alexandre Beliaev (A)

Department of Research and Development, BIAL - Portela & Ca. S.A., S Mamede do Coronado, Portugal.

László E Kiss (LE)

Department of Research and Development, BIAL - Portela & Ca. S.A., S Mamede do Coronado, Portugal.

Maria João Bonifácio (MJ)

Department of Research and Development, BIAL - Portela & Ca. S.A., S Mamede do Coronado, Portugal.

Joerg Holenz (J)

Department of Research and Development, BIAL - Portela & Ca. S.A., S Mamede do Coronado, Portugal.

Patrício Soares-da-Silva (P)

Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal and MedInUp - Center for Drug Discovery and Innovative Medicines, University of Porto, 4200 Porto, Portugal.

Ana Isabel Loureiro (AI)

Department of Research and Development, BIAL - Portela & Ca. S.A., S Mamede do Coronado, Portugal.

Classifications MeSH